corticosteroids

0.0(0)
Studied by 7 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/107

encourage image

There's no tags or description

Looks like no tags are added yet.

108 Terms

1
New cards

1. Q: [Corticosteroids – Definition] What are corticosteroids (CSs) and how may they be broadly defined?



  • Corticosteroids (CSs) are hormones produced in the cortex of the adrenal gland

  • CSs may be broadly defined as: glucocorticoids; mineralocorticoids


2
New cards

 [Glucocorticoids – Natural hormone] What is the natural glucocorticoid?

Hydrocortisone (cortisol).

3
New cards

[Glucocorticoids – HPA axis] How is the production of the natural glucocorticoid controlled and what is this termed?

  • It is produced under the control of the hypothalamus, which secretes corticotrophin-releasing hormone to stimulate the pituitary to secrete adrenocorticotrophic hormone

  • This is termed the Hypothalamic-pituitary-adrenal (HPA) axis


4
New cards

Cortisol – Diurnal production] What is the daily (diurnal) pattern of cortisol production?



  • Cortisol production is diurnal, with a peak early in the morning

  • Followed by a decline and then a secondary, smaller peak in the late afternoon

  • Figure on the slide: highest in the morning, lowest in the evening


5
New cards

 [Mineralocorticoids – Natural hormone] What is the major natural mineralocorticoid and in response to which axis is it produced?



Aldosterone, produced in response to the renin-angiotensin-aldosterone (RAA) axis.



6
New cards

 [Aldosterone – RAA axis figure] Which components are labelled in the RAA axis figure on slide 4?

  • Molecules labelled: Angiotensinogen; Renin; Angiotensin I; Angiotensin Converting Enzyme (ACE); Angiotensin II; Aldosterone

  • Organs labelled: Liver; Kidney; Lungs; Adrenals; Heart; Arteries

  • Outcomes labelled: Sodium & Water Retention; Increased BP; Vasoconstriction


7
New cards

[Classification – Hydrocortisone and prednisone] What are the dosage forms of hydrocortisone and of prednisone (dehydrocortisone)?

  • Hydrocortisone - amp. 100 mg

  • Prednisone (Dehydrocortisone) - tab. 1 and 5 mg


8
New cards

[Classification – Prednisolone] What are the dosage form, relative potency and route of use of prednisolone?

  • tab. 5 mg

  • Five times more potent than hydrocortisone as a glucocorticoid but has less mineralocorticoid action

  • Used orally


9
New cards

 [Classification – Methylprednisolone (Solu-Medrol)] What are the dosage form, relative potency and routes of use of methylprednisolone (Solu-Medrol)?

  • Sterile powder + solvent 40; 125; 250; 500 mg

  • More potent than prednisolone

  • Can be given orally and parenterally


10
New cards

 [Classification – Betamethasone and dexamethasone] What are the dosage forms of betamethasone (Celestone) and of dexamethasone?

  • Betamethasone (Celestone) - tabl. 0.5 mg, amp.

  • Dexamethasone - tab. 0.5 mg, amp.


11
New cards

[Classification – Dexamethasone and betamethasone] How potent are dexamethasone and betamethasone compared with hydrocortisone, and how are they given?

  • About 20 times more potent than hydrocortisone

  • Little mineralocorticoid activity

  • Given orally or parenterally


12
New cards

[Classification – Inhaled CSs] Which inhaled CSs are named on the slides and what are they used for?

  • Beclometasone (Becotide) and Fluticasone (Flixotide)

  • Very potent glucocorticoids used topically by inhalation to treat asthma


13
New cards

 [Glucocorticoids – Mechanism of action] What are the steps in the mechanism of action of glucocorticoids?

  • Bind to receptors in the cytoplasm

  • The hormone-receptor complex is transported into the cell nucleus, where it binds to steroid-responsive element on DNA

  • The complex acts as a transcription factorSlide 7


14
New cards

 [Glucocorticoids – Mechanism of action: gene regulation] How does the glucocorticoid-receptor complex turn genes on or off, and what is the result?

  • Turns genes on when complexed with coactivators

  • Turns genes off when complexed with corepressors

  • The result is stimulation or inhibition of protein synthesis


15
New cards

 [Glucocorticoids – Mechanism of action figure] What does the slide 7 figure show?

  • Corticosteroids → Cytoplasmic receptor protein → Glucocorticoid response element → Transcription of m-RNA → New protein synthesis

  • Total time 30 – 60 mins


16
New cards

[Glucocorticoids – Carbohydrate metabolism] What are the effects of glucocorticoids on carbohydrate metabolism?



  • Promote gluconeogenesis

  • Stimulate the formation of glycogen in the liver

  • Peripheral utilisation of glucose is decreased, and blood glucose may increase


17
New cards

[Glucocorticoids – Protein metabolism] What are the effects of glucocorticoids on protein metabolism?

  • Catabolism is increased

  • Break down muscles and the matrix of bones, thinning of skin

  • Increased plasma level of free amino acids


18
New cards

 [Glucocorticoids – Fat metabolism] What are the effects of glucocorticoids on fat metabolism?

  • Glucocorticoids facilitate action of growth hormone and adrenalin (permissive action) – lipolysis

  • Enhance the action of insulin – lipogenesis and fat deposition

  • Redistribution of fats in different areas of the body

  • Peripheral adipocytes are less sensitive to insulin, but in face and neck predominant action – deposition of fats in face, neck and shoulder – moon face, buffalo hump

  • FLAG (slide 9): the slide lists both lipolysis and lipogenesis/fat deposition; kept as written.


19
New cards

[Glucocorticoids – Calcium metabolism] What are the effects of glucocorticoids on calcium metabolism?

  • Decreased absorption of Ca2+ in GIT

  • Increased Ca2+ excretion


20
New cards

[Glucocorticoids – Mineralocorticoid actions] What mineralocorticoid actions do glucocorticoids have?

  • Retention of Na+ and water

  • Loss of K+


21
New cards

[Glucocorticoids – GIT] What is the effect of glucocorticoids on the GIT?

Increased gastric acid secretion.



22
New cards

: [Glucocorticoids – Skeletal muscles] What does an excess level of glucocorticoids lead to in skeletal muscles and why?

  • Muscular weakness and wasting

  • Due to hypokalaemia and increased protein breakdown


23
New cards

[Glucocorticoids – CNS] What is the CNS effect of glucocorticoids?

Euphoria – in pharmacological doses.

24
New cards

[Glucocorticoids – Blood: lymphoid tissue] What is the effect of glucocorticoids on lymphoid tissue?

  • Destruction of lymphoid tissue – modest in normal patients

  • In presence of malignancy of lymphatic cells – lytic actions are significant (apoptosis) – used in lymphomas


25
New cards

[Glucocorticoids – Blood: cell counts] How do glucocorticoids change blood cell counts?

  • Decrease in eosinophils, basophils, monocytes, and lymphocytes

  • Increased hemoglobin, red blood cells, platelets


26
New cards

 [Glucocorticoids – Resistance to stress] How do glucocorticoids increase resistance to stress?

  • Released in times of physiological stress

  • By raising plasma glucose and amino acid levels, glucocorticoids provide the body with energy


27
New cards

 [Glucocorticoids – Therapeutic effects] Which therapeutic effects of glucocorticoids are listed?

Anti-inflammatory effect; immunosuppressive effect; antiallergic effect.

28
New cards

[Glucocorticoids – Anti-inflammatory effect] What plays the central role in the anti-inflammatory action of glucocorticoids?

Inhibit phospholipase A2 and hence the release of arachidonic acid (the precursor of the prostaglandins and leukotrienes)

29
New cards

[Glucocorticoids – Anti-inflammatory effect] What are the characteristics of the anti-inflammatory effect of glucocorticoids?

  • Suppress inflammatory response to all noxious stimuli: pathogens, chemical, physical and immune mediated

  • Underlying cause of disease is not affected

  • Anti-inflammatory effect is non-specific and covers all components of inflammation


30
New cards

[Corticosteroids vs NSAIDs – Arachidonic acid figure] Which steps are inhibited by corticosteroids and by NSAIDs in the slide 14 figure?

  • Corticosteroids inhibit the step between Phospholipid and Arachidonic Acid

  • NSAIDs inhibit the Cyclooxygenase step, which leads to Prostaglandins

  • Other pathways (like Lipooxygenase) lead to other inflammatory mediators (i.e. proteins, leukotriens)


31
New cards

[Glucocorticoids – Immunosuppressive and antiallergic effect] Through which direct and indirect actions do glucocorticoids produce the immunosuppressive and antiallergic effect?

  • Direct effect on concentration, distribution and actions of immune cells (lymphocytopenia, monocytopenia)

  • Indirect action – inhibit interleukin production and cross-talking between immune cells

  • Inhibit complement system


32
New cards

 [Glucocorticoids – Immunosuppressive and antiallergic effect] Which types of hypersensitivity and which immune response do glucocorticoids suppress?

  • Suppresses all types of hypersensitivity including delayed hypersensitivity

  • Cause greater suppression of cellular-mediated immune response


33
New cards

[Glucocorticoids – Pharmacokinetics: routes] By which routes are glucocorticoids administered?

Oral, intravenous, intramuscularly, intra-articular (for example, into arthritic joints), topical, via inhalation or intranasal delivery.

34
New cards

[Glucocorticoids – Pharmacokinetics: topical and inhaled] What is the consequence of absorption of topical and inhaled glucocorticoids?

All topical and inhaled glucocorticoids are absorbed to some extent and, therefore, have the potential to cause ADRs and HPA axis suppression

35
New cards

[Glucocorticoids – Pharmacokinetics: binding, metabolism, excretion] What are the plasma protein binding, metabolism and excretion of glucocorticoids?

  • Highly bound to plasma proteins, mostly corticosteroid-binding globulin

  • Metabolized in the liver by oxidation (CYP enzymes)

  • Excretion - by the kidney


36
New cards

[CSs – Replacement therapy] For which condition are physiologic doses of CSs used for replacement therapy?

Primary and secondary adrenal insufficiency such as Addison's disease.

37
New cards

 [CSs – Replacement therapy regimen] How is the daily dose of CSs given in replacement therapy, and what else is necessary?

  • Two-thirds of the daily dose is given in the morning and one-third is given in the afternoon

  • The goal of this regimen is to mimic the normal diurnal variation in cortisol levels

  • Administration of fludrocortisone, a potent synthetic mineralocorticoid, is also necessary


38
New cards

[Addison's disease – Oral manifestations] What are the oral manifestations of Addison's disease?

Black-bluish plaques, mainly affecting buccal mucosa but can also be seen on the gums, palate, tongue and lips.

39
New cards

[Addison's disease – Figure on slide 18] Which features of Addison's disease are shown in the slide 18 figure?

  • Adrenal glands not produce sufficient steroid hormones

  • Skin: hyperpigmentation; vitiligo

  • Low blood pressure; weakness; weight loss

  • Gastrointestinal: nausea; diarrhea; vomiting; constipation; abdominal pain


40
New cards

: [Addison's disease – Adrenal crisis] Which signs are listed for adrenal crisis in Addison's disease (slide 18 figure)?

  • Fever; syncope; convulsions

  • Hypoglycemia; hyponatremia

  • Severe vomiting and diarrhea


41
New cards

: [CSs – Therapeutic use 2: supraphysiologic doses] For what are supraphysiologic doses of CSs used?

Their anti-inflammatory effects.

42
New cards

[CSs – Therapeutic use 3: immunosuppressive] When are corticosteroids used for their immunosuppressive effects?

In organ transplant patients and those with autoimmune disorders.

43
New cards

 [CSs – Therapeutic use 4: chemotherapy] How are corticosteroids used in chemotherapy?

As part of chemotherapy for acute leukemias and lymphomas.

44
New cards

[CSs – Anti-inflammatory therapy] In which conditions are CSs used as anti-inflammatory therapy (reduce inflammation in various conditions)?

  • Bronchial asthma

  • Glomerulonephritis

  • Inflammatory bowel disease

  • Rheumatoid arthritis

  • Inflammatory skin conditions

  • Other autoimmune disease

  • Inflammatory and allergic eye disease

  • Brain edema, etc


45
New cards

[CSs – Anti-allergic therapy] In which conditions are CSs used as anti-allergic therapy?

  • Anaphylactic shock

  • Allergic rhinitis

  • Allergic conjunctivitis, skin disease, etc.


46
New cards

 [CSs in dentistry – Oral surgery] What are the uses of CSs in oral surgery?

  • After dental surgical procedures – treatment of postoperative pain, edema and trismus e.g. after 3rd molar surgery

  • Prevention of alveolar osteitis


47
New cards

[CSs in dentistry – Temporomandibular joint disorder] How are CSs used in temporomandibular joint disorder?

: Intra-articular injection of prednisolone or dexamethasone – used to relieve symptoms (temporarily or permanently).

48
New cards

 [CSs in dentistry – Endodontics] How are CSs used in endodontics?

  • Pulpal hypersensitivity (trauma, bacterial invasion of pulp) - glucocorticoids can be used as a component of endodontic sealer as anti-inflammatory agents

  • CSs are usually mixed with antiseptics such as zinc oxide, eugenol and are used as root canal sealers


49
New cards

[CSs in dentistry – Conditions on slide 24] Which conditions are listed for CS use on slide 24?



  • Oral submucous fibrosis

  • Recurrent aphthous stomatitis

  • Desquamative gingivitis

  • Angular stomatitis/cheilitis

  • Traumatic ulcers, etc.

  • FLAG (slide 24): this list has no sub-heading on the slide.


50
New cards

Q: [CSs in dentistry – Benign lesions] Which benign lesions are listed for CS use?

  • Central giant cell granuloma (intralesional injection)

  • Hemangioma


51
New cards

Corticosteroids – Principles of treatment

51. Q: [Topical CSs – Patient instructions] What should patients prescribed topical CSs in an adherent vehicle be instructed to do?



  • Apply a small amount to the target area after meals

  • Not to eat or drink for at least 30 min

  • Not to rub the topical CSs in, because this can produce irritation


52
New cards

 [Topical CSs – Applications per day] How many applications per day are given for high potency and low potency topical CSs?

  • High potency CSs – 2 to 3 times

  • Low potency CSs – 5 to 10 times

  • FLAG (slide 26): application numbers kept exactly as written.


53
New cards

[CS-containing mouth rinses – Principles of treatment] Why are CS-containing mouth rinses used?

CSs are released more readily to oral mucosa when aqueous solution is applied, and drug is in contact with all lesions

54
New cards

 [Systemic CSs – Principles of treatment 1–3] What are principles 1–3 for systemic CS treatment?

  • Once daily dosing is usually preferred for oral glucocorticoids

  • Corticosteroids are usually started at high doses and then reduced to the lowest level at which disease activity is suppressed or withdrawn altogether if possible

  • Whenever possible topical treatment is preferable so that ADRs are minimized


55
New cards

 [Systemic CSs – Timing of dosing] When should GCs be given and why?

  • GCs should be given in the morning 6-10 AM

  • In order to mimic the normal diurnal cycle and reduce the risk of adrenal suppression


56
New cards

 [Systemic CSs – Alternate day therapy] What does alternate day therapy allow?

It allows the HPA axis to recover (on - off days).

57
New cards

[CSs – Withdrawal after long-term use] How must CS treatment be withdrawn after long-term use and why?

  • Must be gradual (over several months) to allow the HPA to recover

  • Otherwise, the patient may experience an acute adrenal insufficiency


58
New cards

Corticosteroids – Adverse drug reactions (ADRs)

58. Q: [CSs – ADRs (slide 29)] Which ADRs of corticosteroids are listed on slide 29?



  • Mood changes e.g. euphoria

  • Increased intraocular pressure - risk of glaucoma

  • Cataract

  • Gastric ulcer

  • Hyperglycemia

  • Osteoporosis


59
New cards

Q: [CSs – ADRs (slide 30)] Which ADRs of corticosteroids are listed on slide 30?

  • Retention of sodium and water, peripheral edema

  • Hypertension

  • Thinning of the skin, striae

  • Increased risk of infections

  • Impaired wound healing

  • Growth retardation in children

  • Adrenal suppression – should be stopped gradually !!!


60
New cards

Q: [CSs – Cushing's syndrome figure] Which features are labelled in the Cushing's syndrome figure on slide 31?

  • Personality Change; Moon Face; Susceptibility to Infection; Males: Gynecomastia; Fat Deposits On Face and Back Of Shoulders; Osteoporosis

  • Hyperglycemia; CNS Irritability; NA & Fluid Retention (Edema); Thin Extremities; GI Distress- Acid

  • Females: Amenorrhea, Hirsutism; Thin Skin; Purple Striae; Bruises & Petechiae


61
New cards

Q: [CSs – ADRs in the mouth] What ADRs in the mouth can prolonged topical CS therapy cause?

  • Atrophy of oral mucosa

  • Disturbed wound healing

  • Oral fungal infections (thrush)

  • Perioral dermatitis, etc.


62
New cards

 Mineralocorticoids

62. Q: [Mineralocorticoids – Effects] What are the effects of mineralocorticoids?



  • Cause Na+ and water retention - increase Na+ reuptake in the distal tubule in exchange for K+

  • Increased excretion of K+ and H+


63
New cards

Q: [Aldosterone and fludrocortisone – Therapeutic use] Is aldosterone used therapeutically and what is fludrocortisone used for?

  • Aldosterone is not used therapeutically

  • Fludrocortisone is used in the replacement therapy for patient with adrenal insufficiency

  • Has no glucocorticoid activity

  • FLAG (slide 33): 'no glucocorticoid activity' is stated as an absolute; kept as written.


64
New cards

Q: [Fludrocortisone – Dosage form] What is the dosage form of fludrocortisone?

 Fludrocortisone (Cortineff) - tab. 100 μg.

65
New cards

Insulin – Basics, mechanism of action, pharmacokinetics

65. Q: [Insulin – Definition and secretion] What is insulin and what most often triggers its secretion?



  • Insulin is a polypeptide produced by the beta cells of the pancreatic islets

  • Secretion is most often triggered by increased blood glucose, which is taken up by the glucose transporter into the β cells of the pancreas


66
New cards

Q: [Insulin – Mechanism of action: carbohydrate metabolism] What are the effects of insulin on carbohydrate metabolism?

  • Insulin allows the active uptake of glucose and its utilization in muscle and fat cells

  • Stimulates synthesis of glycogen (from glucose) in the liver and skeletal muscles

  • Inhibits gluconeogenesis (from amino acids, free fatty acids and glycerol) in the liver


67
New cards

 Q: [Insulin – Mechanism of action: lipid and protein metabolism] What are the effects of insulin on lipid and protein metabolism (anabolic action)?

  • Inhibits lipolysis and stimulates triglyceride synthesis

  • Stimulates protein synthesis and inhibits protein breakdown in skeletal muscles and other cells


68
New cards

 Q: [Insulin – Effects diagram on slide 37] Which insulin effects are marked for liver, adipose tissue and skeletal muscle in the slide 37 diagram?

  • Liver: Glycogenesis (+); Glycogenolysis (−); Gluconeogenesis (−)

  • Adipose: Lipogenesis (+); Lipolysis (−)

  • Skeletal muscle: Glycolysis (+); Protein Synthesis (+); Proteolysis (−)

  • Pancreas: β cells → Insulin; α cells → Glucagon


69
New cards

 Q: [Insulin – Pharmacokinetics: administration] How must insulin be administered?

  • Insulin must be administered parenteraly, usually by s.c. injection

  • Short-acting preparations may also be given i.v.


70
New cards

 Q: [Insulin – Pharmacokinetics: metabolism and half-life] Where is insulin metabolized and what is its plasma half-life?

  • It is metabolized primarily in liver and to a smaller extent in kidney and muscles

  • The plasma t½ is 5–9 min


71
New cards

Q: [Insulin preparations – Origin] From what were insulin preparations originally derived and what problem did this cause?

  • Originally derived from pigs (porcine insulin) or from cattle (beef insulin)

  • They contained ~1% of other proteins which were potentially antigenic and, as a result antibodies sometimes developed

  • This was avoided by the development of highly purified porcine insulin (Slide 39)


72
New cards

Q: [Insulin preparations – Human insulin and insulin analogues] How are human insulin and insulin analogues produced?

  • Human insulin: produced by recombinant DNA technology using strains of Escherichia coli or yeast that are genetically altered to contain the gene for human insulin

  • Insulin analogues: produced by chemical modification of the amino acid sequence; the result is improved pharmacokinetic properties (Slide 39)


73
New cards

Q: [Insulin preparations – Short-acting] What are the onset/peak, duration and administration of short-acting insulin preparations?

  • Peak effect at about 1-2 hours when given s.c.

  • Duration of action of about 4-8 hours

  • Should be injected subcutaneously 30 minutes before a meal

  • May also be given i.v.

  • FLAG (slides 40 vs 45): the slide 45 figure shows Regular insulin peaking in 1 to 5 hours. (Slide 40)


74
New cards

Q: [Insulin preparations – Short-acting] Which preparations are listed as short-acting insulins?

  • Actrapid HM - flac. 400 UI/10 ml

  • Actrapid HM Penfill - flac. 100 UI/1 ml - 3 ml

  • Humulin R - flac. 400 UI/10 ml

  • Insuman Rapid - flac. 400 UI/10 ml (Slide 40)


75
New cards

Q: [Insulin preparations – Very-short acting analogs] What are the properties, timing of injection and preparations of very-short acting insulin analogs?

  • A quicker onset, and a shorter duration of action after subcutaneous injection

  • Peak levels of insulin lispro are seen at 30 to 90 minutes – used to avoid postprandial surge in blood glucose

  • Should be injected subcutaneously in the 15 minutes preceding a meal or within 15 to 20 minutes after starting a meal

  • Preparations: Insulin Lispro (Humalog); Insulin aspart (NovoRapid); Insulin glulisine (Apidra)

  • FLAG (slides 41 vs 45): the slide 45 figure shows Lispro peaking in 0.5 to 2.5 hours. (Slide 41)


76
New cards

Q: [Insulin preparations – Intermediate-acting] What are the properties, use and preparations of intermediate-acting insulins?

  • Have insulin complexed with a zinc salt or protamine so that particles form → insulin is then slowly released from these particles

  • The peak effect is at about 3-6 h, duration of action is of about 12-24 hours

  • Used for basal (fasting) control and is usually given along with rapid- or short-acting insulin for mealtime control

  • Should only be given subcutaneously (never IV)

  • Preparations: Actraphane HM - flac. 400 UI/10 ml; Humulin N - flac. 400 UI/10 ml

  • FLAG (slides 42 vs 45): the slide 45 figure shows ‘HPN’ peaking in 6 to 14 hours. (Slide 42)


77
New cards

Q: [Insulin preparations – Long-acting (crystalline insulin zinc suspension)] What are the properties and preparation of long-acting insulins?

  • Have the insulin-zinc complex formed as crystals, which break down more slowly still

  • The peak effect is at 5-12 h and the duration of effect is 15-30 hours

  • Insulin Ultratard HM - flac. 400 UI/10 ml (Slide 43)


78
New cards

Q: [Insulin preparations – Insulin combinations] What are insulin combinations and which are listed?

  • Premixed combinations of short-acting and intermediate-acting human insulins

  • Humulin M1; M2; M3; M4; M5 - flac. 400 UI/10 ml

  • Mixtard 10; 20; 30; 40; 50 HM - flac. 400 UI/10 ml (Slide 43)


79
New cards

Q: [Insulin preparations – Very-long-acting analogues] What are the properties, use and preparations of very-long-acting insulin analogues?

  • Slower onset and a flat, prolonged hypoglycemic effect with no peak → more reliable and consistent control of blood sugar

  • Used for basal control and should only be administered subcutaneously

  • Insulin glargine (Lantus)

  • Insulin detemir (Levemir) (Slide 44)


80
New cards

Q: [Insulin preparations – Figure on slide 45] Which onset labels and peak statements does the ‘Types of insulin – Onset, Peak, and Duration’ figure show?

  • Lispro: 15-30 min; ‘I start rapidly and peak in 0.5 to 2.5 hours’

  • Regular: 30-60 min; ‘I start fairly fast and peak in 1 to 5 hours’

  • HPN: 60-120 min; ‘I start more slowly and peak in 6 to 14 hours’

  • Lantus: 70 min; ‘I’m there for the long haul with no peak effect’

  • Message: ‘Prevent hypoglycemia! Know the onset, peak, and duration of insulins!’

  • FLAG (slide 45): the pink time labels are not captioned as ‘onset’ on the figure, and several peak values differ from slides 40–42. (Slide 45)


81
New cards

Q: [Insulin – Regimens] What do standard and intensive insulin therapy involve?

  • Standard insulin therapy involves twice-daily injections (before breakfast and the evening meal)

  • Intensive treatment: long-acting insulin or insulin analog once a day supplemented around mealtimes with injection of short-acting insulin or analog three times a day (Slide 46)


82
New cards

Q: [Insulin – ADRs 1–3] Which ADRs 1–3 of insulin are listed on slide 46?

  1. Lipodystrophy – atrophy or hypertrophy at the site of injection

  1. Allergy

  1. Insulin resistance (Slide 46)


83
New cards

Q: [Insulin – ADR 4: Hypoglycemia] What causes insulin-induced hypoglycemia, what are its symptoms and how is it treated?

  • Results from imbalance between glucose intake (e.g., missing a meal), glucose utilisation (e.g., unusual exercise) and insulin dose

  • Symptoms due to sympathetic activation: tachycardia, anxiety, sweating, etc.

  • Symptoms due to neuroglycopenia: visual disturbances, drowsiness, aggression, coma

  • Treatment is by administration of carbohydrate orally to a conscious patient, or i.v. glucose, or i.m. glucagon (Slide 47)


84
New cards

Q: [Oral antidiabetic drugs – Classification] For which type of diabetes are oral antidiabetic drugs used and how are they classified?

  • For type 2 DM

  • Sulfonylureas

  • Insulin secretagogues (glinides)

  • Biguanides

  • Thiazolidinediones

  • Glucosidase inhibitors

  • Dipeptidyl peptidase-4 inhibitors

  • Incretin mimetics

  • Sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors) (Slide 48)


85
New cards

Q: [Sulfonylureas – Drugs] Which sulfonylureas are listed and in what dosage forms?

  • Glibenclamide (Glyburide) – tab. 5 mg

  • Gliclazide (Diaprel MR – tab. 30 mg)

  • Glimepiride (Amaryl) – tab. 1 mg, 2 mg and 3 mg (Slide 49)


86
New cards

Q: [Sulfonylureas – Mechanism of action] What is the mechanism of action of sulfonylureas?

  • Stimulate release of endogenous insulin from the pancreas and so are only effective if the beta cells are functional

  • In addition, sulfonylureas may reduce hepatic glucose production by lowering glucagon levels (Slide 50)


87
New cards

Q: [Sulfonylureas – Pharmacokinetics] What are the absorption, protein binding, placental passage, elimination and cautions for sulfonylureas?

  • Well absorbed from the gastrointestinal tract – oral antidiabetic drugs

  • Highly bound to plasma proteins and can be displaced from protein-binding sites by other drugs

  • Cross the placental barrier – contraindicated in pregnancy

  • Metabolized by the liver and are excreted in the urine and feces

  • Should be used with caution in patients with hepatic or renal insufficiency, since accumulation of sulfonylureas may cause hypoglycemia (Slide 51)


88
New cards

Q: [Sulfonylureas – ADRs] Which ADRs of sulfonylureas are listed?

  • Hypoglycemia

  • Weight gain (hyperinsulinemia)

  • Gastrointestinal upsets

  • Hypersensitivity (Slide 52)


89
New cards

Q: [Sulfonylureas – Drug interactions] Which drugs interact with sulfonylureas and with what effect?

  • Sulfonylureas are heavily protein bound and their actions may be increased by other drugs that compete for the binding sites, e.g., sulfonamides, NSAIDs → hypoglycemia

  • Beta-blockers cause hypoglycemia and may potentiate the effects of sulfonylureas

  • Enzyme inhibitors (chloramphenicol, metronidazole, azole antifungals, macrolide antibiotics) enhance the glucose lowering-effect → hypoglycemia

  • Corticosteroids, diuretics, β-sympathomimetics cause hyperglycemia and reduce the effect of sulfonylureas (Slide 53)


90
New cards

Q: [Glinides (Repaglinide) – Properties] What are the dosage form, mechanism, onset and duration, ADRs and interaction restriction of glinides (repaglinide)?

  • Repaglinide – tab. 1 mg

  • Not chemically a sulfonylurea but it acts in a similar way – increase the release of insulin

  • In contrast to the sulfonylureas, the glinides have a very rapid onset and a short duration of action

  • ADRs: hypoglycemia – lower risk than that with sulfonylureas!!!; weight gain

  • Glinides should not be used in combination with sulfonylureas due to overlapping mechanisms of action; this would increase the risk of serious hypoglycemia

  • FLAG (slide 54): the slide title reads ‘Insulin’ although the content is about glinides. (Slide 54)


91
New cards

Q: [Biguanides (Metformin) – Dosage forms and effects] What are the dosage forms and effects of metformin?

  • Metformin – tab. 500 mg; 850 mg; 1000 mg

  • Decreases hepatic gluconeogenesis

  • Increases peripheral utilisation of glucose

  • Decreases absorption of glucose

  • Does not require functioning beta cells

  • Slide 56 cartoon (Metformin, Glucophage): slows down glucose production in the liver; blocks absorption of sugar in the intestines; helps the muscles use the sugar more efficiently; can be used with other hypoglycemics (Slide 55-56)


92
New cards

Q: [Biguanides (Metformin) – Pharmacokinetics] What are the absorption, protein binding, metabolism and excretion of metformin?

  • Good oral absorption

  • No protein binding

  • No metabolism

  • Excretion – urine (Slide 57)


93
New cards

Q: [Biguanides (Metformin) – ADRs] Which ADRs of metformin are listed?

  • !!! Lactic acidosis can occur if metformin is used in patients with coexisting liver or renal disease or congestive heart failure

  • Gastrointestinal upsets – nausea, vomiting

  • Megaloblastic anemia due to decreased absorption of vitamin B12

  • Does not cause hypoglycemia !!! (Slide 57)


94
New cards

Q: [Biguanides (Metformin) – Use] What is the place of metformin in the treatment of type 2 diabetes?

  • Metformin is recommended as the initial drug of choice for type 2 diabetes

  • It may be used alone or in combination with other oral agents or insulin (Slide 58)


95
New cards

Q: [Thiazolidinediones (Pioglitazone) – Dosage form and mechanism] What are the dosage form and mechanism of action of pioglitazone?

  • Pioglitazone – tab. 15; 30 and 45 mg

  • Increase cell sensitivity to insulin (insulin sensitizers)

  • Act as agonists for the peroxisome proliferator–activated receptor-γ (PPARγ) – a nuclear hormone receptor (Slide 59)


96
New cards

Q: [Thiazolidinediones (Pioglitazone) – ADRs] Which ADRs of thiazolidinediones are listed?

  • Hepatitis

  • Fluid retention and heart failure

  • Increased risk of bladder cancer and bone fractures – restricted use!!! (Slide 59)


97
New cards

Q: [α-Glucosidase inhibitors (Acarbose) – Dosage form, mechanism, ADRs] What are the dosage form, mechanism of action and ADRs of acarbose?

  • Acarbose (Glucobay) - tab. 50 mg

  • Reversibly inhibit α-glucosidase enzymes that break down carbohydrates into glucose and other simple sugars that can be absorbed

  • When taken at the start of a meal, these drugs delay the digestion of carbohydrates, resulting in lower postprandial glucose levels

  • ADRs: GI – diarrhea and abdominal pain

  • Slide 61 figure: compares carbohydrate absorption without acarbose and with acarbose (labels: Stomach; Upper small intestine – Jejunum; Lower small intestine – Ileum) (Slide 60-61)


98
New cards

Q: [Incretin mimetics – Incretin hormones] Which two incretin hormones are released from the GI tract in response to a meal, and what do incretin hormones do?

  • Glucagon like peptide-1 (GLP-1)

  • Glucose-dependent insulinotropic polypeptide (GIP)

  • Increase insulin secretion – responsible for 60% to 70% of postprandial insulin secretion

  • Decrease postprandial glucagon secretion

  • Slow gastric emptying time and reduce food intake by enhancing satiety (a feeling of fullness) – weight gain is reduced (Slide 62)


99
New cards

Q: [Incretin mimetics – GLP-1 / GLP-1R agonists figure] Which effects of GLP-1 or GLP-1R agonists are shown per organ in the slide 63 figure?

  • GI Tract: ↓ Gastric emptying; ↓ GI motility; ↑ Acid secretion

  • Brain: ↓ Appetite; ↑ Satiety; ↑ Energy expenditure

  • Heart: ↓ Blood pressure; ↑ Heart rate; ↑ Myocardial contractility

  • Kidney: ↑ Natriuresis

  • Pancreas: ↓ Glucagon secretion; ↑ Insulin secretion; ↑ Insulin biosynthesis; ↑ β-cell proliferation

  • ↑ Insulin Sensitivity – Liver: ↓ Hepatic glucose production; Adipose tissue: ↑ Lyposis, ↑ FFA synthesis, ↑ Glucose uptake; Muscle: ↑ Glycogen synthesis, ↑ Glucose oxidation

  • FLAG (slide 63): the figure spells ‘Lyposis’; kept as written. (Slide 63)


100
New cards

Q: [Incretin mimetics – Definition and drugs] What are incretin mimetics and which drugs are listed?

  • Incretin mimetics are analogs of GLP-1, acting as GLP-1 receptor agonists

  • Exenatide (Byetta) - inj.

  • Liraglutide (victosa) - inj.

  • Semaglutide (Ozempic)

  • Trizaptide (Zepbound)

  • FLAG (slide 64): ‘victosa’ and ‘Trizaptide’ are kept as spelled on the slide; no route or dosing is given for Trizaptide. (Slide 62, 64)